Hengrui Drug Application Accepted for Priority Review
Hengrui said its marketing authorization application for injectable Ruikang trastuzumab has been accepted and included in the priority review program.
Related stories
IW Report Says Trump's Tariffs Failed to Cut US Trade Deficit
A report by the German Economic Institute (IW) says U.S. tariffs did not reduce the trade deficit.
M impact | REGULATION | Oct 30, 2026, 07:01 AM UTC
US Offers Audi a Tariff on Imports, Insider Says
A source identified as an insider says the United States offered Audi a tariff on imports.
M impact | REGULATION | Oct 30, 2026, 05:25 AM UTC
Beijing Urban Construction Design Public Float Falls Below 25% Minimum
The company’s public float was 23.70% as of Oct. 30, below the required 25% minimum.
L impact | REGULATION | Oct 30, 2026, 04:03 AM UTC
USFDA Approves Sun Pharma’s Supplemental Biologics License Application for Ilumya
M impact | REGULATION | Oct 30, 2026, 02:37 AM UTC
Indonesia Exempts Coal for Off-Grid Plants From Domestic Market Obligation
M impact | REGULATION | Oct 30, 2026, 02:13 AM UTC
Prosecutors Appeal Oh Se-hoon’s Second-Trial Acquittal
A special counsel appealed Oh Se-hoon’s acquittal in a second trial on political-fund law charges.
L impact | REGULATION | Oct 30, 2026, 01:51 AM UTC